|Bid||0.00 x 800|
|Ask||82.75 x 1100|
|Day's Range||81.67 - 82.54|
|52 Week Range||73.69 - 89.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 24, 2018|
|Forward Dividend & Yield||2.25 (2.77%)|
|1y Target Est||90.45|
Eli Lilly’s (LLY) Human Pharmaceutical Products segment includes neuroscience products including Cymbalta, Strattera, Prozac, and Zyprexa. Overall sales for neuroscience products declined in the first quarter, driven by lower sales of Cymbalta, Strattera, Prozac, and Zyprexa.
Eli Lilly’s (LLY) Human Pharmaceutical Products segment includes products from various therapeutic areas, including neuroscience, cardiovascular, endocrine, oncology, and others. Check out all the data we have added to our quote pages.
Major equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Co. (NYSE: BMY), Eli Lilly and Co. (NYSE: LLY), and GW Pharmaceuticals PLC (NASDAQ: GWPH). All you have to do is sign up today for this free limited time offer by clicking the link below.
A possible reshaping of how some Medicare drugs are paid for has drug companies feeling sick. Health and Human Services Secretary Alex Azar's plan to consolidate at least some Part B prescription drugs under Part D could cost pharmaceutical companies real money since while there are no price negotiations under Part B, Part D includes discount, rebates and negotiating tools. Part B drugs are those that are administered in a doctor's office, clinic, hospital or someplace beyond the patient's home.
Eli Lilly’s (LLY) products are classified into two business segments: Human Pharmaceutical Products and Animal Health. The above chart compares the segment-wise quarterly revenues for Eli Lilly since the first quarter of 2017. The US markets reported a 10% growth in revenues in the first quarter, driven by an 8% positive impact of prices and a 2% growth in volumes.
Eli Lilly’s (LLY) revenues surpassed Wall Street analysts’ estimates and reported a 9% growth to $5.7 billion for the first quarter. The above graph compares Eli Lilly’s quarterly revenues since the first quarter of 2017 and includes estimates for this year’s second quarter. Wall Street analysts estimate revenues of $6 billion for the second quarter, which would be a 3.7% growth compared to $5.8 billion in the second quarter of 2017.
Eli Lilly (LLY) reported EPS of $1.34 and revenues of $5.7 billion in the first quarter. Both results surpassed Wall Street analysts’ estimates.
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.
said late Thursday, May 17, they have obtained approval from the U.S. Food and Drug Administration for Aimovig, a migraine prevention drug for adults. The drug is the first treatment green-lighted by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor, thought to play a key role in the disease. "We believe Amgen will benefit significantly from its first mover advantage and ultimately retain 35-40% market share long term," Leerink Partners LLC analyst Geoffrey C. Porges wrote in a note on Friday.
AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.
The U.S. Food and Drug Administration on Thursday approved Amgen Inc's drug Aimovig for the prevention of migraine headaches in adults. The drug, given monthly by self injection, will have a list price of $6,900 a year, or $575 a month, the company said. Any discounts or rebates will depend on negotiations with health plans, said Amgen spokeswoman Kristen Davis.
The company reported net income of close to $115.9 million in the quarter, a YoY rise of ~594% and a sequential rise of 201%. Exelixis reported diluted GAAP (generally accepted accounting principles) EPS (earnings per share) of close to $0.37, a YoY rise of ~585% and a sequential rise of 201%. Analysts expect Exelixis to report revenue of close to $723 million in 2018, a YoY rise of ~59.8%.
Teva Pharmaceutical (TEVA) provided an increased guidance for this fiscal year during its first-quarter earnings release on May 3. The company has made an upward revision to its guidance for this fiscal year. Teva reported better-than-expected results in the fiscal first quarter.
LONDON, UK / ACCESSWIRE / May 17, 2018 / If you want access to our free research report on Eli Lilly and Co. (NYSE: LLY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LLY as the Company's latest news hit the wire. On May 15, 2018, the Company announced that a Phase-3 study evaluating galcanezumab in patients with episodic cluster headache met its primary endpoint, demonstrating statistically significant differences in the reduction of weekly cluster headache attacks compared to placebo across weeks one to three of the two-month, double-blind treatment period. There were also a statistically significantly greater percentage of patients treated with galcanezumab who achieved at least a 50% reduction in weekly cluster headache attacks compared to placebo at Week 3, the gated secondary endpoint.
First presentation of findings from the ramucirumab REACH-2 study - the first positive Phase 3 hepatocellular carcinoma trial in a biomarker-selected population Research across the MONARCH clinical development ...
Eli Lilly's (LLY) galcanezumab meets the primary endpoint in a late-stage study evaluating it for the prevention of episodic cluster headache.
During Teva’s (TEVA) 1Q18 earnings release on May 3, the company provided an update on the approval and launch of its anti-CGRP (calcitonin gene-related peptide) monoclonal antibody Fremanezumab, a preventive migraine treatment. The company stated that it now doesn’t expect to get FDA (U.S. Food and Drug Administration) approval for Fremanezumab in mid-June as it had earlier estimated. The reason that Teva doesn’t expect approval in June is that Celltrion, which is Teva’s API (active pharmaceutical ingredients) supplier of Fremanezumab, got a warning letter from the FDA in 2017.
The high-profile departure would be the latest in a string of exits of top investors in recent years from one of Silicon Valley's oldest and most successful venture firms.
In 1Q18, Valeant Pharmaceuticals’ (VRX) revenues witnessed an ~5.0% decline to reach $2.0 billion. Valeant Pharmaceuticals had an operating loss and net loss of ~$2.3 billion and ~$2.7 billion, respectively, in 1Q18. To learn more about its 1Q18 financial data, please read How Valeant Pharmaceuticals Performed in 1Q18.
Eli Lilly & Co. said Tuesday a phase 3 trial of galcanezumab for the treatment of episodic cluster headaches met its primary endpoint, and also achieved its secondary endpoint. Lilly said it is now working with regulatory agencies to determine the best path forward for galcanezumab. "Cluster headache can be difficult to evaluate in clinical studies, which has contributed to few available treatment options for cluster headache, often considered the most severe pain one can experience," said Christi Shaw, president of Lilly Bio-Medicines.
Eli Lilly and Co said on Tuesday that patients with episodic cluster headache attacks had reduced symptoms when treated with its experimental migraine drug galcanezumab compared to those treated with a placebo. Patients with episodic cluster headache treated with a 300 mg dose of galcanezumab experienced an average of 8.7 fewer headache attacks per week over a three-week period. Patients who participated in the trial had a baseline average of 17.5 cluster headache attacks per week.
INDIANAPOLIS, May 15, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache, demonstrating statistically significant differences in the reduction of weekly cluster headache attacks compared to placebo across weeks one to three of the two-month, double-blind treatment period. A statistically significantly greater percentage of patients treated with galcanezumab also achieved at least a 50 percent reduction in weekly cluster headache attacks compared to placebo at Week 3, the gated secondary endpoint. The observed safety and tolerability profile was consistent with previous studies that evaluated galcanezumab for the prevention of migraine.
WeissLaw is investigating whether ARMO's Board acted to maximize shareholder value prior to entering into the agreement. Notably, at least one analyst set a target price of $75.00 per share, or $25.00 above the offer price. Moreover, the deal is a strategic transaction that will expand LLY's drug portfolio and provide LLY a foothold in the very lucrative cancer immunotherapy industry.
Eli Lilly and Co will buy AurKa Pharma Inc in a deal potentially worth up to $575 million, the U.S. drugmaker said on Monday, seeking access to the privately-held firm's experimental cancer treatment for solid tumors. The deal is Lilly's second in less than a week that aims to broaden its portfolio of lucrative cancer drugs. On Thursday, Lilly said it would buy Armo BioSciences Inc for about $1.6 billion.